Merck Products Give Ono Pharma Renewed Life In Japan

TOKYO - Ono Pharma's drug portfolio is "going from maturity to decline," according to a Bank America Merrill Lynch analyst, but there are signs that in-licensed products from Merck, particularly antiemetic Emend (aprepitant), could bring new life to the company